Fast Brain MRI in Children With Suspected Brain Tumor
Launched by KAROLINSKA UNIVERSITY HOSPITAL · Mar 8, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of MRI called Neuromix, which is designed to take images of the brain faster than the usual MRI methods. The goal is to see if this new MRI can help doctors diagnose brain tumors in children more effectively. If your child is between 0 and 18 years old and has been referred for an MRI because they have a diagnosed or suspected brain tumor, they may be eligible to participate in this study.
Participants in the trial will receive both the standard MRI and the new Neuromix MRI, allowing doctors to compare the two. This research is important as it could lead to quicker and more accurate diagnoses for children with brain tumors. However, children who need to be sedated for the MRI, have an unstable medical condition, or have had their MRI exam stopped won't be able to join the study. Overall, this trial aims to improve how we detect brain tumors in young patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 0-18 years.
- • Pediatric subjects with diagnosed or suspected brain tumor
- • Referral routine MRI study.
- Exclusion Criteria:
- • MRI planned without sedation
- • Aborted MR exam
- • Unstable patient
About Karolinska University Hospital
Karolinska University Hospital is a leading academic medical center in Sweden, renowned for its commitment to advanced healthcare research and innovative clinical practices. As a key sponsor of clinical trials, the hospital leverages its extensive expertise in medical research and collaboration with Karolinska Institutet, one of the world's foremost medical universities. The institution is dedicated to enhancing patient care through rigorous scientific investigation, focusing on a wide range of therapeutic areas. With a multidisciplinary approach and a strong emphasis on translational medicine, Karolinska University Hospital aims to bridge the gap between laboratory findings and clinical application, ultimately striving to improve health outcomes and advance medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Anna Falk Delgado, Ass Prof
Principal Investigator
Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials